Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

4172 - An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer


08 Oct 2016


Poster Display


Thomas Winder


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


T. Winder1, F. Posch2, E. Asamer2, M. Stotz2, A. Siebenhüner1, K. Schlick3, T. Magnes4, P. Samaras1, J. Szkandera2, P. Clavien5, D. Neureiter6, R. Greil7, B.C. Pestalozzi1, H. Stoeger8, A. Gerger8, A. Egle3, M. Pichler8

Author affiliations

  • 1 Medizinische Onkologie, Universitätsspital Zürich, 8091 - Zürich/CH
  • 2 Department Of Internal Medicine, Medical University Graz, 8036 - Graz/AT
  • 3 Division Of Oncology, Paracelsus University Hospital Salzburg, 2050 - Salzburg/AT
  • 4 Iiird Medical Department With Hematology And Medical Oncology, Oncologic Center, Paracelsus University Hospital Salzburg, 5020 - Salzburg/AT
  • 5 Klinik Für Viszeral- Und Transplantationschirurgie, University Hospital Zürich, Zürich/CH
  • 6 Pathology, Paracelsus University Hospital Salzburg, Salzburg/AT
  • 7 Head Of The Iiird Medical Department, Paracelsus University Hospital Salzburg, 5020 - Salzburg/AT
  • 8 Clinical Division Of Medical Oncology, Department Of Internal Medicine, Medical University Graz, 8036 Graz - Graz/AT


Abstract 4172


Both fibrinogen and C-reactive protein (CRP) are biomarkers of systemic inflammation, but differ regarding their half-life, underlying pathophysiological triggers, genetic background and cellular as well as molecular effects. The aim of this study was to investigate the fibrinogen/CRP ratio (FCR) as a prognostic blood-based biomarker for survival outcome in patients with pancreatic cancer.


609 consecutive patients with pancreatic adenocarcinoma (Stage I-III: n = 253 (41.5%), Stage IV: n = 356 (58.5%) from a tri-center cohort study (Austria and Switzerland) had routine measurements of fibrinogen and CRP levels at the time of diagnosis, and were followed until the occurrence of death-from-any-cause. The FCR was defined as the ratio of fibrinogen (in mg/dL) to CRP (in mg/L).


During a median follow-up period of 3.8 years (range: 3 days-8.4 years), 511 (83.9%) patients died (1-, 3-, and 5-year overall survival (OS) probabilities (95%CI): 45.2% (41.1-49.2), 14.0% (11.2-17.2), and 7.4% (5.0-10.4), respectively. Patients with an elevated FCR, defined as an FCR > 75th percentile of the FCR distribution (cut-off: 145.3 units), had a significantly higher 1-year OS than patients ≤ this cut-off (60.2% vs. 40.2%, p 


In this large tri-center cohort of patients with pancreatic adenocarcinoma, we observed a strong association between a high FCR and a lower risk of death in patients with metastatic disease but not in patients with localized disease. An elevated FCR at baseline defines a novel clinical subset of patients with metastatic pancreatic cancer who have a remarkable survival advantage.

Clinical trial identification

Legal entity responsible for the study



University Graz, Salzburg, Zurich


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings